Willow Biosciences Past Earnings Performance

Past criteria checks 0/6

Willow Biosciences has been growing earnings at an average annual rate of 31.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 71.8% per year.

Key information

31.6%

Earnings growth rate

47.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate71.8%
Return on equity-3,956.4%
Net Margin-268.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Willow Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:3D7 Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243-840
30 Jun 242-940
31 Mar 241-1140
31 Dec 231-1360
30 Sep 232-1580
30 Jun 231-1790
31 Mar 231-17100
31 Dec 221-1590
30 Sep 220-159-9
30 Jun 220-79-6
31 Mar 22029-3
31 Dec 210-690
30 Sep 210-16711
30 Jun 210-2779
31 Mar 210-4468
31 Dec 200-3467
30 Sep 200-2286
30 Jun 200-1686
31 Mar 200-45104
31 Dec 190-4583
30 Sep 190-4252
30 Jun 190-4140
31 Mar 190-220
31 Dec 180-220
30 Sep 180-220
31 Dec 170-220
31 Dec 160-110

Quality Earnings: 3D7 is currently unprofitable.

Growing Profit Margin: 3D7 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 3D7 is unprofitable, but has reduced losses over the past 5 years at a rate of 31.6% per year.

Accelerating Growth: Unable to compare 3D7's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3D7 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 3D7 has a negative Return on Equity (-3956.41%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 07:18
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Willow Biosciences Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David KideckelATB Capital Markets